Monoclonal antibodies targeting small molecules for diagnostic & therapeutic use

ImmuSmol's pipeline of small molecule antibodies


ImmuSmol is developing 3 personalized medicine programs based on proprietary monoclonal antibodies raised against pathometabolites.

Advantages of small molecule antibodies for therapy

Core benefits of monoclonal antibodies

Now accounting for over 60 % of top-selling drugs, monoclonal antibodies feature attractive pharmaceutical properties:

ImmuSmol partnering strategy

ImmuSmol builds alliances with large pharmaceutical companies to accelerate product development, through: